K.J. Harrison & Partners Inc raised its stake in shares of Zymeworks Inc (NYSE:ZYME) by 25.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,000 shares of the company’s stock after acquiring an additional 3,000 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in Zymeworks were worth $219,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in shares of Zymeworks during the 2nd quarter worth approximately $4,981,000. Millennium Management LLC purchased a new stake in shares of Zymeworks during the second quarter worth $1,442,000. Acadian Asset Management LLC purchased a new stake in shares of Zymeworks during the third quarter worth $1,319,000. Stanley Laman Group Ltd. purchased a new position in Zymeworks in the third quarter valued at $887,000. Finally, Wells Fargo & Company MN boosted its stake in Zymeworks by 103.0% in the third quarter. Wells Fargo & Company MN now owns 89,794 shares of the company’s stock valued at $1,410,000 after acquiring an additional 45,560 shares in the last quarter. 26.44% of the stock is owned by institutional investors.
In other Zymeworks news, major shareholder Eli & Co Lilly sold 250,000 shares of the stock in a transaction on Thursday, January 31st. The shares were sold at an average price of $16.00, for a total value of $4,000,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Several research analysts recently issued reports on the stock. TheStreet raised shares of Zymeworks from a “d” rating to a “c-” rating in a report on Friday, January 11th. Zacks Investment Research upgraded shares of Zymeworks from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Tuesday, October 23rd. Canaccord Genuity set a $21.00 target price on shares of Zymeworks and gave the stock a “buy” rating in a research report on Wednesday, November 28th. Raymond James set a $29.00 price objective on shares of Zymeworks and gave the company an “outperform” rating in a research report on Monday, December 10th. Finally, ValuEngine raised shares of Zymeworks from a “hold” rating to a “buy” rating in a research note on Monday, January 7th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $23.00.
Zymeworks stock traded up $0.20 during mid-day trading on Friday, reaching $15.71. The company had a trading volume of 27,529 shares, compared to its average volume of 134,131. Zymeworks Inc has a 52 week low of $9.57 and a 52 week high of $29.00. The company has a market cap of $496.01 million, a PE ratio of -27.56 and a beta of 1.57.
WARNING: This piece was originally reported by Highlight Press and is the sole property of of Highlight Press. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://highlightpress.com/2019/02/16/zymeworks-inc-zyme-shares-bought-by-k-j-harrison-partners-inc.html.
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer.
Further Reading: The Discount Rate – What You Need to Know
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.